Abstract
Ribonucleases degrade RNA, now considered an important drug target. The parent member of this protein superfamily is bovine pancreatic RNase A that functions as a digestive enzyme. Other physiological roles and activities have been ascribed to more recently discovered members of this superfamily. Angiogenin was isolated by following angiogenic activity from cell culture media conditioned by colon cancer cells. ONCONASE kills tumor cells in vitro and in vivo and has advanced to a phase IIIb confirmatory clinical trial for the treatment of unresectable malignant mesothelioma. All three of these RNA degrading enzymes have been used to generate immunoRNases; chemical conjugates and ligand- RNase fusion proteins, for cancer therapy. The properties of each of these RNases are described along with the increasingly sophisticated construction of recombinant immunoRNases. The advantages of using RNase as an antibody payload is compared to using plant or bacterial toxins in the construction of immunotoxins, a related strategy for specifically killing malignant cells.
Current Pharmaceutical Design
Title: Ribonucleases and ImmunoRNases as Anticancer Drugs
Volume: 15 Issue: 23
Author(s): S. M. Rybak, M. A.E. Arndt, T. Schirrmann, S. Dubel and J. Krauss
Affiliation:
Abstract: Ribonucleases degrade RNA, now considered an important drug target. The parent member of this protein superfamily is bovine pancreatic RNase A that functions as a digestive enzyme. Other physiological roles and activities have been ascribed to more recently discovered members of this superfamily. Angiogenin was isolated by following angiogenic activity from cell culture media conditioned by colon cancer cells. ONCONASE kills tumor cells in vitro and in vivo and has advanced to a phase IIIb confirmatory clinical trial for the treatment of unresectable malignant mesothelioma. All three of these RNA degrading enzymes have been used to generate immunoRNases; chemical conjugates and ligand- RNase fusion proteins, for cancer therapy. The properties of each of these RNases are described along with the increasingly sophisticated construction of recombinant immunoRNases. The advantages of using RNase as an antibody payload is compared to using plant or bacterial toxins in the construction of immunotoxins, a related strategy for specifically killing malignant cells.
Export Options
About this article
Cite this article as:
Rybak M. S., Arndt A.E. M., Schirrmann T., Dubel S. and Krauss J., Ribonucleases and ImmunoRNases as Anticancer Drugs, Current Pharmaceutical Design 2009; 15 (23) . https://dx.doi.org/10.2174/138161209788923921
DOI https://dx.doi.org/10.2174/138161209788923921 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiogenesis Inhibition: State of the Art, Forgotten Strategies and New Perspectives in Cancer Therapy
Current Cancer Therapy Reviews State of Research Tracks and Property Protection of Photodynamic Sensitizers and Delivery Methodologies
Recent Patents on Chemical Engineering TGF Beta Inhibition for Cancer Therapy
Current Cancer Drug Targets Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
Current Medicinal Chemistry Going 3D – Cell Culture Approaches for Stem Cell Research and Therapy
Current Tissue Engineering (Discontinued) Effects of the Natural Isoflavonoid Genistein on Growth, Signaling Pathways and Gene Expression of Matrix Macromolecules by Breast Cancer Cells
Mini-Reviews in Medicinal Chemistry Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism A Better Platinum-Based Anticancer Drug Yet to Come?
Anti-Cancer Agents in Medicinal Chemistry Application of Pharmacogenomics to Dietary Cancer Chemoprevention
Current Pharmacogenomics MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine
Current Gene Therapy To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Arginine Deprivation as a Targeted Therapy for Cancer
Current Pharmaceutical Design Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets Structural and Bioactive Properties of 3-O-Methylfunicone
Mini-Reviews in Medicinal Chemistry Viral-Mediated Gene Transfer for Cancer Treatment
Current Pharmaceutical Biotechnology γ-Tocotrienol Induces Apoptosis in Human T Cell Lymphoma through Activation of Both Intrinsic and Extrinsic Pathways
Current Pharmaceutical Design Pathway of Inflammation due to Asbestiform Fiber “Fluoro-edenite” Exposure: An Update
Current Respiratory Medicine Reviews Expression and Functions of Vasoactive Substances Regulated by Hypoxia-Inducible Factor-1 in Chronic Hypoxemia
Cardiovascular & Hematological Agents in Medicinal Chemistry